Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schumer/Waxman Call For Industry Groups To Condemn Generic Drug Payoffs

This article was originally published in The Pink Sheet Daily

Executive Summary

In letters to PhRMA and GPhA, legislators point to FTC report detailing industry settlements as a sign of growing anti-competitive activity.

You may also be interested in...



Supreme Court Denies Certiorari To FTC v. Schering-Plough

The high court denies the Federal Trade Commission’s petition to hear the case regarding issues raised by brand companies’ reverse payments to generic firms.

Supreme Court Denies Certiorari To FTC v. Schering-Plough

The high court denies the Federal Trade Commission’s petition to hear the case regarding issues raised by brand companies’ reverse payments to generic firms.

Unsettling Settlements: FTC Alarmed By Increasing Brand/Generic Deals

The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel